Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Colorectal Neoplasms 4Neoplasm Metastasis 2Carcinoma 2Adenocarcinoma 2Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Liver Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 11Fluorouracil 10pembrolizumab 9Cisplatin 9Radiotherapy 7Carboplatin 6Esophagectomy 5Nivolumab 4Drug Therapy 4Radiotherapy, Intensity-Modulated 3Leucovorin 3Chemoradiotherapy 3Cetuximab 3Capecitabine 3durvalumab 2atezolizumab 2Oxaliplatin 2Ipilimumab 2spartalizumab 1sintilimab 1selinexor 1regorafenib 1prexasertib 1osimertinib 1niraparib 1nilotinib 1nedaplatin 1nanocis 1fludarabine 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × selinexor × Gastrointestinal × Clear all
NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
192 enrolled 29 charts
CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡